{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:39:22Z","timestamp":1791931162099,"version":"4.3.4"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.pharmthera.2023.108355","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:38:14Z","timestamp":1675424294000},"page":"108355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["How to get rid of itching"],"prefix":"10.1016","volume":"243","author":[{"given":"Ashley","family":"Vander Does","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.burns.2012.05.014","article-title":"The use of botulinum toxin in the management of burns itching: Preliminary results","volume":"38","author":"Akhtar","year":"2012","journal-title":"Burns: Journal of the International Society for Burn Injuries"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-662-44605-8_13","article-title":"Protease-activated receptors and itch","volume":"226","author":"Akiyama","year":"2015","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb0015","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0020","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2133.2011.10241.x","article-title":"Expression of tachykinins and their receptors in plaque psoriasis with pruritus","volume":"164","author":"Amatya","year":"2011","journal-title":"The British Journal of Dermatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108355_bb0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/j.pain.0000000000001220","article-title":"Alloknesis and hyperknesis-mechanisms, assessment methodology, and clinical implications of itch sensitization","volume":"159","author":"Andersen","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0030","series-title":"Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial [press release]","author":"Arena Pharmaceuticals","year":"2020"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: A review","volume":"82","author":"Avila","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaci.2016.12.980","article-title":"Substance P activates Mas-related G protein-coupled receptors to induce itch","volume":"140","author":"Azimi","year":"2017","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108355_bb0045","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for chronic spontaneous urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0055","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ced.13398","article-title":"Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist","volume":"43","author":"Bilir","year":"2018","journal-title":"Clinical and Experimental Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0075","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20082242","article-title":"Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome","volume":"206","author":"Briot","year":"2009","journal-title":"The Journal of Experimental Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0080","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.0022-202x.2001.01498.x","article-title":"The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor","volume":"117","author":"Burbach","year":"2001","journal-title":"The Journal of Investigative Dermatology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb0085","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/exd.14034","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice","volume":"28","author":"Campion","year":"2019","journal-title":"Experimental Dermatology"},{"issue":"7887","key":"10.1016\/j.pharmthera.2023.108355_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0095","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4103\/ijdvl.IJDVL_41_17","article-title":"Anti-pruritic efficacies of doxycycline and erythromycin in the treatment of acne vulgaris: A randomized single-blinded pilot study","volume":"84","author":"Cao","year":"2018","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0100","first-page":"e191","article-title":"Efficacy of a topical proteinase-activated receptor-2 inhibitor on cowhage-induced pruritus: A randomized placebo-controlled double-blind study","volume":"31","author":"Cao","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology\u202f: JEADV"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108355_bb0105","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/cn5000919","article-title":"TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation","volume":"5","author":"Caterina","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Cedeno-Laurent","year":"2015","journal-title":"Clinical Immunology (Orlando, Fla.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaci.2017.02.001","article-title":"Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis","volume":"140","author":"Cevikbas","year":"2017","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0120","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1038\/s41467-020-16859-5","article-title":"Central circuit mechanisms of itch","volume":"11","author":"Chen","year":"2020","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0125","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2019.09.014","article-title":"Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial","volume":"82","author":"Chiou","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0130","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.154","article-title":"Evaluation of apremilast in chronic pruritus of unknown origin: A proof-of-concept, phase 2a, open-label, single-arm clinical trial","volume":"3","author":"Clark","year":"2020","journal-title":"Health Science Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1006\/clin.1996.0159","article-title":"Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism","volume":"81","author":"Columbo","year":"1996","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0150","first-page":"20","article-title":"Oncostatin M blockade alleviates itch","volume":"21","author":"Crunkhorn","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/aps.2017.152","article-title":"A pivotal role for the activation of TRPV3 channel in itch sensations induced by the natural skin sensitizer carvacrol","volume":"39","author":"Cui","year":"2018","journal-title":"Acta Pharmacologica Sinica"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: A cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"The Journal of Investigative Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.npep.2006.06.002","article-title":"Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes","volume":"40","author":"Dallos","year":"2006","journal-title":"Neuropeptides"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1152\/jn.00206.2012","article-title":"Pruriceptive spinothalamic tract neurons: Physiological properties and projection targets in the primate","volume":"108","author":"Davidson","year":"2012","journal-title":"Journal of Neurophysiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00000542-198811000-00022","article-title":"A blinded study using nalbuphine for prevention of pruritus induced by epidural fentanyl","volume":"69","author":"Davies","year":"1988","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb0180","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.pain.2014.05.006","article-title":"Paroxysmal itch caused by gain-of-function Nav1.7 mutation","volume":"155","author":"Devigili","year":"2014","journal-title":"Pain"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2023.108355_bb0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/brain\/awt158","article-title":"The neurology of itch","volume":"137","author":"Dhand","year":"2014","journal-title":"Brain\u202f: A Journal of Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0190","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bja.2020.06.057","article-title":"Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates","volume":"125","author":"Ding","year":"2020","journal-title":"British Journal of Anaesthesia"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41374-019-0334-6","article-title":"Role of macrophage TRPV4 in inflammation","volume":"100","author":"Dutta","year":"2020","journal-title":"Laboratory Investigation; A Journal of Technical Methods and Pathology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108355_bb0200","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0205","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3452","article-title":"The OX40 axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamadermatol.2021.0179","article-title":"Association of wildfire air pollution and health care use for atopic dermatitis and itch","volume":"157","author":"Fadadu","year":"2021","journal-title":"JAMA Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0215","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0220","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","article-title":"Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients","volume":"5","author":"Fishbane","year":"2020","journal-title":"Kidney International Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb0225","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00403-014-1481-7","article-title":"Role of AhR\/ARNT system in skin homeostasis","volume":"306","author":"Furue","year":"2014","journal-title":"Archives of Dermatological Research"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0230","series-title":"Galderma presents new nemolizumab data at EADV [press release]","author":"Galderma","year":"2021"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0235","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15162","article-title":"Cannabinoids interaction with transient receptor potential family and implications in the treatment of rosacea","volume":"34","author":"Garbutcheon-Singh","year":"2021","journal-title":"Dermatologic Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0245","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/toxins10040143","article-title":"Antipruritic effects of botulinum neurotoxins","volume":"10","author":"Gazerani","year":"2018","journal-title":"Toxins"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0250","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2133.2009.09305.x","article-title":"Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin","volume":"161","author":"Gazerani","year":"2009","journal-title":"The British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227817","article-title":"Tissue-resident macrophages can be generated de novo in adult human skin from resident progenitor cells during substance P-mediated neurogenic inflammation ex vivo","volume":"15","author":"Gherardini","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0260","doi-asserted-by":"crossref","first-page":"AB164","DOI":"10.1016\/j.jaad.2021.06.669","article-title":"27874 Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis","volume":"85","author":"Gold","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0265","doi-asserted-by":"crossref","DOI":"10.25251\/skin.5.supp.41","article-title":"Roflumilast cream 0.3% improved the severity and impact of itch in patients with chronic plaque psoriasis in the phase 3 DERMIS-1 and DERMIS-2 studies","volume":"5","author":"Gooderham","year":"2021","journal-title":"SKIN The Journal of Cutaneous Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb0270","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40256-018-00320-6","article-title":"Clinical pharmacokinetics, safety, and tolerability of a novel, first-in-class TRPV4 ion channel inhibitor, GSK2798745, in healthy and heart failure subjects","volume":"19","author":"Goyal","year":"2019","journal-title":"American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108355_bb0280","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1021\/acs.jmedchem.6b01850","article-title":"Sulfonamides as selective NaV1.7 inhibitors: Optimizing potency, pharmacokinetics, and metabolic properties to obtain atropisomeric quinolinone (AM-0466) that affords robust in vivo activity","volume":"60","author":"Graceffa","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0285","first-page":"3043","article-title":"The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion","volume":"165","author":"Gramaglia","year":"2000","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/jdv.17764","article-title":"Novel functions of S1P in chronic itchy and inflammatory skin diseases","volume":"36","author":"Gray","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology\u202f: JEADV"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0295","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuron.2019.01.012","article-title":"A mast-cell-specific receptor mediates neurogenic inflammation and pain","volume":"101","author":"Green","year":"2019","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0300","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: A placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"The British Journal of Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bib1166","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0305","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0310","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.neuron.2018.06.039","article-title":"miRNA-711 binds and activates TRPA1 extracellularly to evoke acute and chronic pruritus","volume":"99","author":"Han","year":"2018","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108355_bb0315","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/bph.15390","article-title":"A plant-derived TRPV3 inhibitor suppresses pain and itch","volume":"178","author":"Han","year":"2021","journal-title":"British Journal of Pharmacology"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2023.108355_bb0320","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000371890","article-title":"S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission","volume":"95","author":"Haruna","year":"2015","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0325","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jid.2019.09.012","article-title":"Mechanisms of itch in stasis dermatitis: Significant role of IL-31 from macrophages","volume":"140","author":"Hashimoto","year":"2020","journal-title":"The Journal of Investigative Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0330","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108355_bb0335","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jid.2021.03.009","article-title":"Periostin, an emerging player in itch sensation","volume":"141","author":"Hashimoto","year":"2021","journal-title":"The Journal of Investigative Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0340","doi-asserted-by":"crossref","first-page":"adv00375","DOI":"10.2340\/00015555-3702","article-title":"Dermal periostin: A new player in itch of prurigo nodularis","volume":"101","author":"Hashimoto","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb0345","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/exd.13705","article-title":"Possible roles of basophils in chronic itch","volume":"28","author":"Hashimoto","year":"2019","journal-title":"Experimental Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0350","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2340\/00015555-3086","article-title":"Antipruritic effects of janus kinase inhibitor tofacitinib in a mouse model of psoriasis","volume":"99","author":"Hashimoto","year":"2019","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0355","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ni.3614","article-title":"The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin","volume":"18","author":"Hidaka","year":"2017","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0360","doi-asserted-by":"crossref","first-page":"255","DOI":"10.23736\/S0375-9393.18.12751-9","article-title":"Effect of adding nalbuphine to intrathecal bupivacaine with morphine on postoperative nausea and vomiting and pruritus after elective cesarean delivery: A randomized double blinded study","volume":"85","author":"Ibrahim","year":"2019","journal-title":"Minerva Anestesiologica"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb0365","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/exd.14401","article-title":"The pruritogenic role of the type 2 immune response in diseases associated with chronic itch","volume":"30","author":"Ingrasci","year":"2021","journal-title":"Experimental Dermatology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0375","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","article-title":"OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology","volume":"105","author":"Ishii","year":"2010","journal-title":"Advances in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0380","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/AAC.01540-08","article-title":"Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes","volume":"53","author":"Ishikawa","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108355_bb0385","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/all.13814","article-title":"Periostin: An emerging biomarker for allergic diseases","volume":"74","author":"Izuhara","year":"2019","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0390","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12079-009-0057-3","article-title":"Periostin localizes to cells in normal skin, but is associated with the extracellular matrix during wound repair","volume":"3","author":"Jackson-Boeters","year":"2009","journal-title":"Journal of Cell Communication and Signaling"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0395","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: Results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"The British Journal of Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0400","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0405","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.3390\/ijms22062979","article-title":"Psoriasis: Pathogenesis, comorbidities, and therapy updated","volume":"22","author":"Kanda","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2023.108355_bb0410","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejphar.2011.06.027","article-title":"G protein coupled receptor specificity for C3a and compound 48\/80-induced degranulation in human mast cells: Roles of Mas-related genes MrgX1 and MrgX2","volume":"668","author":"Kashem","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0415","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14669","article-title":"Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits","author":"Kim","year":"2022","journal-title":"Experimental Dermatology"},{"issue":"1S","key":"10.1016\/j.pharmthera.2023.108355_bb0420","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/DER.0000000000000770","article-title":"Rapid improvement of itch associated with atopic dermatitis with abrocitinib is partially independent of overall disease improvement: Results from pooled phase 2b and 3 monotherapy studies","volume":"32","author":"Kim","year":"2021","journal-title":"Dermatitis\u202f: Contact, Atopic, Occupational, Drug"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0425","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/biomedicines10051087","article-title":"Aryl hydrocarbon receptors: Evidence of therapeutic targets in chronic inflammatory skin diseases","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108355_bb0430","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1111\/ijd.12841","article-title":"Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model","volume":"54","author":"Kim","year":"2015","journal-title":"International Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0435","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.alit.2016.10.003","article-title":"The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin","volume":"66","author":"Kittaka","year":"2017","journal-title":"Allergology International : Official Journal of the Japanese Society of Allergology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0440","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.114.215749","article-title":"The histamine H\u2084 receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects","volume":"350","author":"Kollmeier","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb0445","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/intimm\/dxab065","article-title":"The molecular basis for IL-31 production and IL-31-mediated itch transmission: From biology to drug development","volume":"33","author":"Kunimura","year":"2021","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0450","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S316602","article-title":"Immunotargets and therapy for prurigo nodularis","volume":"11","author":"Labib","year":"2022","journal-title":"ImmunoTargets and Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0455","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nchembio.2334","article-title":"In silico design of novel probes for the atypical opioid receptor MRGPRX2","volume":"13","author":"Lansu","year":"2017","journal-title":"Nature Chemical Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0460","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2020.09.028","article-title":"Novel insights into the TRPV3-mediated itch in atopic dermatitis","volume":"147","author":"Larkin","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"24","key":"10.1016\/j.pharmthera.2023.108355_bb0465","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0470","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1038\/srep11676","article-title":"Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates","volume":"5","author":"Lee","year":"2015","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0475","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"The Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0480","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bjd.17455","article-title":"Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: A phase IIb randomized trial","volume":"180","author":"Lee","year":"2019","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0485","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-981-16-4254-8_12","article-title":"TRPV1 in pain and itch","volume":"1349","author":"Li","year":"2021","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"41","key":"10.1016\/j.pharmthera.2023.108355_bb0490","doi-asserted-by":"crossref","first-page":"14795","DOI":"10.1073\/pnas.0507385102","article-title":"Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin","volume":"102","author":"Li","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0495","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/acschemneuro.2c00012","article-title":"Histamine sensitization of the voltage-gated sodium channel Nav1.7 contributes to histaminergic itch in mice","volume":"13","author":"Li","year":"2022","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0370","series-title":"Lilly\u2019s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials [press release]","author":"Lilly Investors","year":"2021"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0500","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ajhg.2012.02.006","article-title":"Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome","volume":"90","author":"Lin","year":"2012","journal-title":"American Journal of Human Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0505","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.mcna.2021.04.007","article-title":"Approach to the patient with chronic pruritus","volume":"105","author":"Lipman","year":"2021","journal-title":"The Medical Clinics of North America"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0510","doi-asserted-by":"crossref","first-page":"AB22","DOI":"10.1016\/j.jaad.2021.06.112","article-title":"The impact of neuropathic itch on patients\u2019 quality of life","volume":"85","author":"Lipman","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0515","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2133.2006.07408.x","article-title":"Substance P receptor expression in human skin keratinocytes and fibroblasts","volume":"155","author":"Liu","year":"2006","journal-title":"The British Journal of Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0520","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12264-012-1207-9","article-title":"Oxidative stress induces itch via activation of transient receptor potential subtype ankyrin 1 in mice","volume":"28","author":"Liu","year":"2012","journal-title":"Neuroscience Bulletin"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0525","article-title":"Formalin itch test: Low-dose formalin induces histamine-independent, TRPA1-mediated itch in mice","volume":"8","author":"Liu","year":"2021","journal-title":"Frontiers in Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0530","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaci.2017.05.051","article-title":"Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch","volume":"141","author":"Luo","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0535","doi-asserted-by":"crossref","DOI":"10.5070\/D3272052393","article-title":"Assessing the effects of topical cannabidiol in patients with atopic dermatitis","volume":"27","author":"Maghfour","year":"2021","journal-title":"Dermatology Online Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0540","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3390\/ijms22063065","article-title":"The role of TRPA1 in skin physiology and pathology","volume":"22","author":"Maglie","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0545","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/ijms24010420","article-title":"Transient receptor potential channels and itch","volume":"24","author":"Mahmoud","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-017-0698-3","article-title":"Upregulation of Mas-related G Protein coupled receptor X2 in asthmatic lung mast cells and its activation by the novel neuropeptide hemokinin-1","volume":"19","author":"Manorak","year":"2018","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.606197","article-title":"Polyphenols and cannabidiol modulate transcriptional regulation of Th1\/Th2 inflammatory genes related to canine atopic dermatitis","volume":"8","author":"Massimini","year":"2021","journal-title":"Frontiers in Veterinary Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108355_bb0560","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1172\/JCI58978","article-title":"Periostin promotes chronic allergic inflammation in response to Th2 cytokines","volume":"122","author":"Masuoka","year":"2012","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0565","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000484573","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus","volume":"46","author":"Mathur","year":"2017","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0570","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaip.2020.11.043","article-title":"Biologics for the use in chronic spontaneous urticaria: When and which","volume":"9","author":"Maurer","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology. In Practice"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0575","series-title":"Itch: Mechanisms and treatment","article-title":"Mrgprs as itch receptors","author":"McNeil","year":"2014"},{"issue":"7542","key":"10.1016\/j.pharmthera.2023.108355_bb0580","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0585","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0590","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that may mediate a component of cholestatic itch","volume":"8","author":"Meixiong","year":"2019","journal-title":"eLife"},{"issue":"21","key":"10.1016\/j.pharmthera.2023.108355_bb0595","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0600","doi-asserted-by":"crossref","first-page":"15551","DOI":"10.1038\/s41598-018-33620-7","article-title":"Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation","volume":"8","author":"Melo","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0605","series-title":"Menlo therapeutics announces results from two phase 3 clinical trials of serlopitant for the treatment of pruritus associated with prurigo nodularis [press release]","author":"Menlo Therapeutics","year":"2020"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0610","series-title":"Menlo therapeutics announces results from phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin [press release]","author":"Menlo Therapeutics","year":"2020"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108355_bb0615","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/jid.2014.226","article-title":"Substance P is upregulated in the serum of patients with chronic spontaneous urticaria","volume":"134","author":"Metz","year":"2014","journal-title":"The Journal of Investigative Dermatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0620","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0300985815574007","article-title":"Expression of periostin in normal, atopic, and nonatopic chronically inflamed canine skin","volume":"52","author":"Mineshige","year":"2015","journal-title":"Veterinary Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0625","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","article-title":"Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb","volume":"150","author":"Miron","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin activation of integrin receptors on sensory neurons induces allergic itch","volume":"31","author":"Mishra","year":"2020","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0635","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31684","article-title":"Keratinocytes mediate innocuous and noxious touch via ATP-P2X4 signaling","volume":"7","author":"Moehring","year":"2018","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0640","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: Getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clinical Reviews in Allergy & Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0645","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12264-017-0200-8","article-title":"Regulation of pain and itch by TRP channels","volume":"34","author":"Moore","year":"2018","journal-title":"Neuroscience Bulletin"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0650","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2021.09.022","article-title":"Circuit mechanisms of itch in the brain","volume":"142","author":"Mu","year":"2022","journal-title":"The Journal of Investigative Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0660","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"The Journal of Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0665","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"Journal of Dermatological Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0675","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.10339","article-title":"Efficacy and safety of difelikefalin in japanese patients with moderate to severe pruritus receiving hemodialysis: A randomized clinical trial","volume":"5","author":"Narita","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0680","first-page":"1021","article-title":"Prolonged antipruritic effect of botulinum toxin type A on cowhage-induced itch","volume":"97","author":"Nattkemper","year":"2017","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0685","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.jid.2020.11.017","article-title":"Cutaneous gene expression in primates with itch","volume":"141","author":"Nattkemper","year":"2021","journal-title":"The Journal of Investigative Dermatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108355_bb0690","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: The expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0695","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: Gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"The Journal of Investigative Dermatology"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb0700","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.bmcl.2012.02.072","article-title":"Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent","volume":"22","author":"Odan","year":"2012","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0705","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0710","doi-asserted-by":"crossref","unstructured":"Ogasawara, H., & Noguchi, M. (2021). Therapeutic potential of MRGPRX2 inhibitors on mast cells. Cells, 10(11), 2906. doi:https:\/\/doi.org\/10.3390\/cells10112906","DOI":"10.3390\/cells10112906"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0715","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555-2780","article-title":"Role of substance P and its receptor neurokinin 1 in chronic prurigo: A randomized, proof-of-concept, controlled trial with topical aprepitant","volume":"98","author":"Ohanyan","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0720","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0725","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.neuroimage.2011.10.099","article-title":"A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch","volume":"59","author":"Papoiu","year":"2012","journal-title":"NeuroImage"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0730","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2020.01.056","article-title":"Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial","volume":"82","author":"Pariser","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0735","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","article-title":"Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD)","volume":"149","author":"Park","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0740","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0745","article-title":"Abrocitinib: A new FDA-approved drug for moderate-to-severe atopic dermatitis","volume":"10600280221096713","author":"Perche","year":"2022","journal-title":"The Annals of Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb0750","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: Beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0755","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.immuni.2020.10.001","article-title":"Substance P release by sensory neurons triggers dendritic cell migration and initiates the type-2 immune response to allergens","volume":"53","author":"Perner","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0760","first-page":"80","article-title":"Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: A pilot study","volume":"15","author":"Pulvirenti","year":"2007","journal-title":"Acta Dermatovenerologica Croatica\u202f: ADC"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0765","series-title":"European Academy of Dermatology and Venereology 30th Congress; Medicom","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis who received background topical therapy in a 26-week, randomized, head-to-head trial [abstract no. D3T01.2B plus presentation]","author":"Reich","year":"2021"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108355_bb0770","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.bmcl.2017.03.085","article-title":"Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice","volume":"27","author":"Roecker","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0775","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(01)00191-1","article-title":"OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells","volume":"15","author":"Rogers","year":"2001","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0780","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bph.12266","article-title":"The role of histamine in neurogenic inflammation","volume":"170","author":"Rosa","year":"2013","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0785","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00281-011-0289-1","article-title":"Protease-activated receptor 2 signaling in inflammation","volume":"34","author":"Rothmeier","year":"2012","journal-title":"Seminars in Immunopathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0790","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: A phase III randomized double-blind, vehicle-controlled trial","volume":"186","author":"Saeki","year":"2022","journal-title":"The British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0795","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/1346-8138.15137","volume":"47","author":"Saeki","year":"2020","journal-title":"The Journal of Dermatology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb0815","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochemical Pharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2023.108355_bb0820","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0625.1998.tb00307.x","article-title":"Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune systems","volume":"7","author":"Scholzen","year":"1998","journal-title":"Experimental Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0825","first-page":"1285","article-title":"Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis","volume":"166","author":"Scholzen","year":"2001","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108355_bb0830","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jid.2020.02.028","article-title":"Enhanced thermal sensitivity of TRPV3 in keratinocytes underlies heat-induced pruritogen release and pruritus in atopic dermatitis","volume":"140","author":"Seo","year":"2020","journal-title":"The Journal of Investigative Dermatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108355_bb0835","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","article-title":"House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation","volume":"20","author":"Serhan","year":"2019","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0840","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.regpep.2013.08.001","article-title":"Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1\/2 and JNK MAPK transcription pathways","volume":"186","author":"Shi","year":"2013","journal-title":"Regulatory Peptides"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb0845","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1523\/JNEUROSCI.4643-06.2007","article-title":"TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase","volume":"27","author":"Shim","year":"2007","journal-title":"The Journal of Neuroscience\u202f: The Official Journal of the Society for Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108355_bb0850","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ajpath.2015.07.015","article-title":"Histamine released from epidermal keratinocytes plays a role in \u03b1-melanocyte-stimulating hormone-induced itching in mice","volume":"185","author":"Shimizu","year":"2015","journal-title":"The American Journal of Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0855","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jaci.2018.10.053","article-title":"Role of P2X3 receptors in scratching behavior in mouse models","volume":"143","author":"Shiratori-Hayashi","year":"2019","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136379","article-title":"Role of TRP ion channels in pruritus","volume":"768","author":"Shirolkar","year":"2022","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0865","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb0870","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0875","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"The British Journal of Dermatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0880","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bib1167","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0885","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"The Journal of Investigative Dermatology"},{"issue":"10246","key":"10.1016\/j.pharmthera.2023.108355_bb0890","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"1S","key":"10.1016\/j.pharmthera.2023.108355_bb0895","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/DER.0000000000000725","article-title":"Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: Results from a phase 2b study with abrocitinib","volume":"32","author":"Simpson","year":"2021","journal-title":"Dermatitis\u202f: Contact, Atopic, Occupational, Drug"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108355_bb0900","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR Agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"The Journal of Investigative Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb0905","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2340\/00015555-2360","article-title":"Effects of apremilast on pruritus and skin discomfort\/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis","volume":"96","author":"Sobell","year":"2016","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0910","author":"Sofen"},{"key":"10.1016\/j.pharmthera.2023.108355_bb0915","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0920","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"St\u00e4nder","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb0925","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00105-006-1180-1","article-title":"Topische Cannabinoidagonisten. Eine effektive, neue M\u00f6glichkeit zur Behandlung von chronischem Pruritus [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]","volume":"57","author":"St\u00e4nder","year":"2006","journal-title":"Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0930","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bjd.18025","article-title":"Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus","volume":"181","author":"St\u00e4nder","year":"2019","journal-title":"The British Journal of Dermatology"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb0935","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0940","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/imr.12635","article-title":"Role of mast cells and basophils in pruritus","volume":"282","author":"Steinhoff","year":"2018","journal-title":"Immunological Reviews"},{"issue":"15","key":"10.1016\/j.pharmthera.2023.108355_bb1168","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1523\/JNEUROSCI.23-15-06176.2003","article-title":"Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin","volume":"23","author":"Steinhoff","year":"2003","journal-title":"The Journal of neuroscience\u202f: the official journal of the Society for Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb0945","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/72247","article-title":"Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism","volume":"6","author":"Steinhoff","year":"2000","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0950","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.1601751","article-title":"Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis","volume":"199","author":"Suvas","year":"2017","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0955","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1774-9987.2005.00271.x","article-title":"Emollients with endocannabinoids in the treatment of uremic pruritus: Discussion of the therapeutic options","volume":"9","author":"Szepietowski","year":"2005","journal-title":"Therapeutic Apheresis and Dialysis\u202f: Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy"},{"issue":"21","key":"10.1016\/j.pharmthera.2023.108355_bb0960","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1128\/MCB.25.21.9360-9368.2005","article-title":"Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions","volume":"25","author":"Tauchi","year":"2005","journal-title":"Molecular and Cellular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108355_bb0965","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/bjd.14391","article-title":"Pathophysiology of pruritus in primary localized cutaneous amyloidosis","volume":"174","author":"Tey","year":"2016","journal-title":"The British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb0970","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11882-020-00979-5","article-title":"Mast cell-specific MRGPRX2: A key modulator of neuro-immune interaction in allergic diseases","volume":"21","author":"Thapaliya","year":"2021","journal-title":"Current Allergy and Asthma Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0975","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/jdv.17813","article-title":"Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis","volume":"36","author":"Thyssen","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology\u202f: JEADV"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108355_bb0980","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1080\/08820139.2022.2083973","article-title":"The effects of cannabinoid agonist, heat shock protein 90 and nitric oxide synthase inhibitors on increasing IL-13 and IL-31 levels in chronic pruritus","volume":"51","author":"Todurga Seven","year":"2022","journal-title":"Immunological Investigations"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0985","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/1346-8138.12317","article-title":"Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications","volume":"41","author":"Tominaga","year":"2014","journal-title":"The Journal of Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb0990","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb0995","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2340\/00015555-2593","article-title":"Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: A dermatocosmetic study","volume":"97","author":"Visse","year":"2017","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb1005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/exd.12606","article-title":"A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves","volume":"24","author":"Wakita","year":"2015","journal-title":"Experimental Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb1010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000437206","article-title":"Health-related quality of life in chronic pruritus: An analysis related to disease etiology, clinical skin conditions and itch intensity","volume":"231","author":"Warlich","year":"2015","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108355_bb1015","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s11136-016-1340-4","article-title":"Health-related quality of life in haemodialysis patients suffering from chronic itch: Results from GEHIS (German Epidemiology Haemodialysis Itch Study)","volume":"25","author":"Weiss","year":"2016","journal-title":"Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"key":"10.1016\/j.pharmthera.2023.108355_bb1020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000446010","article-title":"Epidemiology of itch","volume":"50","author":"Weisshaar","year":"2016","journal-title":"Current Problems in Dermatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb1025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jdv.17816","article-title":"Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase","volume":"36","author":"Weisshaar","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology\u202f: JEADV"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb1030","article-title":"A combined responder analysis of tradipitant demonstrates significant improvements in itch and disease severity","volume":"81","author":"Welsh","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb1035","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/jdv.17090","article-title":"Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: Results from EPIONE, a randomized clinical trial","volume":"35","author":"Welsh","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb1040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb1045","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/biom11081166","article-title":"TRPV1 and TRPA1 channels are both involved downstream of histamine-induced itch","volume":"11","author":"Wilzopolski","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb1050","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaci.2020.12.655","article-title":"A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice","volume":"148","author":"Wolf","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb1055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"The British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb1060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1468-3083.2002.00361.x","article-title":"Adjuvant botulinum toxin A in dyshidrotic hand eczema: A controlled prospective pilot study with left-right comparison","volume":"16","author":"Wollina","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb1065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/ph11040100","article-title":"TRP channels as drug targets to relieve itch","volume":"11","author":"Xie","year":"2018","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb1070","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2018.01.014","article-title":"Prevalence and characteristics of pruritus and association with quality of life in people living with HIV: A cross-sectional study","volume":"55","author":"Xu","year":"2018","journal-title":"Journal of Pain and Symptom Management"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108355_bb1075","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMcp1208814","article-title":"Clinical practice. Chronic pruritus","volume":"368","author":"Yosipovitch","year":"2013","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb1080","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-2893","article-title":"Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor","volume":"98","author":"Yosipovitch","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb1090","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: From mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108355_bb1095","doi-asserted-by":"crossref","DOI":"10.1097\/itx.0000000000000012","article-title":"Effect of crisaborole topical ointment, 2%, on atopic dermatitis\u2013associated pruritus: An extended analysis of 2 phase 3 clinical trials","volume":"3","author":"Yosipovitch","year":"2018","journal-title":"Itch"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108355_bb1100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2340\/00015555-3195","article-title":"Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials","volume":"99","author":"Yosipovitch","year":"2019","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108355_bb1105","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.pharmthera.2023.108355_bb1110","series-title":"Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: Results from a 2nd phase 3 trial (LIBERTY-PN PRIME) [oral presentation]","author":"Yosipovitch","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108355_bb1115","series-title":"Could dupilumab put an end to the therapeutic draught in prurigo nodularis?","author":"Yosipovitch","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108355_bb1120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.pharmthera.2023.108355_bb1125","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: Results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clinical Interventions in Aging"},{"issue":"3 Suppl 1","key":"10.1016\/j.pharmthera.2023.108355_bb1130","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb1135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration","volume":"20","author":"Zeidler","year":"2016","journal-title":"European Journal of Pain (London, England)"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108355_bb1140","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.3390\/ijms20236058","article-title":"3'-O-methylorobol inhibits the voltage-gated sodium channel Nav1.7 with anti-itch efficacy in A histamine-dependent itch mouse model","volume":"20","author":"Zhang","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108355_bb1145","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1621","article-title":"Involvement of sensory neurone-TRPV4 in acute and chronic itch behaviours","volume":"102","author":"Zhang","year":"2022","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108355_bb1150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12967-017-1196-6","article-title":"Up-regulated expression of substance P in CD8+ T cells and NK1R on monocytes of atopic dermatitis","volume":"15","author":"Zhang","year":"2017","journal-title":"Journal of Translational Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108355_bb1155","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jid.2020.01.012","article-title":"PAR2 mediates itch via TRPV3 Signaling In Keratinocytes","volume":"140","author":"Zhao","year":"2020","journal-title":"The Journal of Investigative Dermatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108355_bb1160","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12264-016-0076-z","article-title":"Antioxidants attenuate acute and chronic itch: Peripheral and central mechanisms of oxidative stress in pruritus","volume":"33","author":"Zhou","year":"2017","journal-title":"Neuroscience Bulletin"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108355_bb1165","doi-asserted-by":"crossref","first-page":"AB47","DOI":"10.1016\/j.jaad.2021.06.213","article-title":"Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study","volume":"85","author":"Zirwas","year":"2022","journal-title":"JAAD"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:27:04Z","timestamp":1759012024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":227,"alternative-id":["S0163725823000190"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108355","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to get rid of itching","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108355"}}